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Abstract: The aim of the present study was to investigate the influence of process shear 
stressors on the stability of a model monoclonal antibody, trastuzumab. Trastuzumab, at 
concentrations of 0.4–4.0 mg/mL, was subjected to sonication, freeze-thaw, lyophilisation, 
spray drying and was encapsulated into micro- and nanoparticles. The stressed samples 
were analysed for structural integrity by gel electrophoresis, SDS-PAGE, and size 
exclusion chromatography (SEC), while the conformational integrity was analysed by 
circular dichroism (CD). Biological activity of the stressed trastuzumab was investigated 
by measuring the inhibition of cell proliferation of HER-2 expressing cell lines. Results 
show that trastuzumab was resistant to the process shear stresses applied and to 
microencapsulation processes. At the lowest concentration of 0.4 mg/mL, a low percent 
(<9%) of soluble/reversible aggregates may have been formed. No loss of structural 
integrity, conformation was observed and no significant change in the biological activity of 
trastuzumab was observed (ANOVA; p > 0.05). The results of this study conclude that 
trastuzumab may be resistant to various processing stresses. These findings have important 
implications with respect to pharmaceutical processing of monoclonal antibodies. 
Keywords: trastuzumab; shear stress; stability; size exclusion chromatography; circular 
dichroism; biological activity 
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1. Introduction  
In recent years a number of new monoclonal antibody based therapeutics have reached the market 
for the treatment of diseases such as cancer and immune-mediated diseases and many more are under 
development [1]. These monoclonal antibodies (mAbs) while having very potent therapeutic activity 
exhibit instability related to their structure. This poses various difficulties in their formulation, 
processing, storage and administration. It is extensively reported that these protein based therapeutics 
are labile molecules which can be structurally disrupted when exposed to various physical, thermal or 
chemical stressors [2-5]. Physical disruption of these molecules may manifest as denaturation [6] or 
aggregation [7] and is a common problem which may occur during manufacture, storage and 
administration of proteins including mAbs. Aggregates can form when these molecules are subject to 
various types of agitation or shear as a result of protein exposure to hydrophobic surfaces or air/water 
interfaces [8]. Aggregates formed can be reversible or irreversible and can have reduced activity or are 
inactive and may be immunogenic compared to the native molecule [9]. 
The anti-cancer monoclonal antibody cituximab has been shown to aggregate when subjected to 
stirring stress in a chemically independent manner [10]. Stathopulos et al, 2004 [11] reported that 
sonication induced the formation of aggregates that resemble amyloid in certain proteins. Aggregates 
can also form as a result of exposure to low or high temperatures. The exposure of a monoclonal 
antibody to freeze-thawing may result in aggregate formation via a number of mechanisms such as pH 
mediated conformational changes and adsorption to the ice-liquid interface [12,13]. An increase in 
temperature can also increase protein aggregation via chemical and non-chemical processes [14,15]. 
As a result of their sensitivity to agitation including rapid expulsion from a syringe, the reconstitution 
of mAbs is often recommended by manufacturers to be by gentle swirling and not shaking. 
Monoclonal antibodies may also be subject to structural disruption by chemical means such as 
disulfide formation/exchange, oxidation or fragmentation [16]. Structural disruption may result in a 
marked reduction or indeed complete loss of biological activity and in addition may cause 
immunogenic type reactions [17,18].  
Encapsulation of monoclonal antibodies into micro- and nanoparticulate delivery systems has 
stimulated much interest in the scientific literature [19]. The benefits of such delivery systems include 
protection from degradation, controlled release and ability to target to specific cells and tissues. In 
addition nanoparticulates have the ability to exploit the enhanced permeability and retention effect 
which occurs in solid tumors leading to elevated drug concentrations at the tumor site when compared 
with non-encapsulated drugs [20,21]. These nanoparticulate systems are currently being studied for 
their application to deliver monoclonal antibodies in the treatment of cancer as they offer multiple 
benefits to the patient. A limitation of these systems is that their manufacture exposes the therapeutic 
agent to various stressors which may be deleterious to the active, in particular to biological actives, 
such as proteins including monoclonal antibodies and may render the biological therapeutics inactive 
and/or possibly immunogenic.  
Formulation of nanoparticulate systems exposes these biological molecules to one or more types of 
shear stress including sonication, homogenization and lyophilisation and these may disrupt the 
molecule resulting in the loss of its binding ability and biological activity. While the encapsulation of 
mAbs in such nanoparticulate systems have been studied, the effect of their exposure to the stresses 
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involved has not been examined in detail.  In this study we therefore investigated the effect of various 
shear stresses which commonly occur during the formulation and processing of particulate drug 
delivery systems, both individually and collectively, on the structural integrity and biological activity 
of trastuzumab (tzmAb), a model monoclonal antibody. Trastuzumab (Herceptin®), a recombinant 
humanized IgG1 monoclonal antibody (mAb), is used in the treatment of HER2 over-expressing breast 
cancers. Trastuzumab binds to the extracellular domain of the HER2 receptor and exerts its clinical 
action through inhibition of intracellular signaling via both the mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol 3 kinase (PI3K) pathways [22,23]. Disruption of the molecule can 
affect its binding and hence its biological activity. 
The stressors we examined included sonication, lyophilisation and freeze-thawing. In addition the 
effect of spray drying, a technique which is commonly used in the formulation of microparticles for 
drug delivery by routes such as inhalation was investigated. To study the effect of multiple stressors on 
the stability of the mAb, micro- and nanoparticles containing trastuzumab were subsequently prepared 
using spray drying and solvent evaporation from a double emulsion respectively and the encapsulated 
trastuzumab was analysed for structural integrity and biological activity.  
2. Experimental Section 
2.1. Materials 
 
Reconstituted and diluted trastuzumab (Herceptin®; Roche Products Ireland Ltd.) solutions 
containing 0.4–4 mg/mL trastuzumab were a gift from Fannin Compounding Ireland Ltd. Poly-lactide-
co-glycolide (PLGA, RG504H) polymer polymer was purchased from Boehringer, Ingelheilm, 
Germany. Chitosan of medium molecular weight (240 kDa), polyvinyl alcohol (PVA) of molecular 
weight ~30–70 kDa, were obtained from Sigma-Aldrich (Ireland). All other reagents and HPLC grade 
solvents used were purchased from Sigma-Aldrich (Ireland). 
 
2.2. Application of Mechanical/Shear Stresses on Trastuzumab Solutions 
 
Various process shear stresses were applied to trastuzumab solutions of concentrations 0.4 to  
4 mg/mL as described below.  
 
2.2.1. Sonication 
 
Trastuzumab solutions of 0.4 and 4.0 mg/mL were sonicated using a probe sonicator (Bransonic 
2510 Sonicator, Branson Ultrasonics Corporation, Connecticut, USA) at 1 Watt for 1 min and  
3 min. Additionally, the higher concentration of 4.0 mg/mL trastuzumab solution was sonicated at a 
higher intensity of 3 Watts for 1 min and 3 min.  
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2.2.2. Freeze-Thaw Cycle 
 
 Trastuzumab solutions at concentrations of 0.4 and 4 mg/mL were subjected to freeze thawing 
cycles by freezing each solution at –80 °C for 50 min and thawing at 4 °C. This cycle was repeated up 
to 6 times for each concentration studied.  
 
2.2.3. Lyophilisation (Freeze-Drying) 
 
Trastuzumab solution at a concentration of 2mg/mL was lyophilized using the following protocol: 
Solutions were first frozen at –80 °C and subsequently freeze dried using a FreeZone 6 Liter Benchtop 
freeze drier (model no. 7752030, Labconco, Missouri, USA) operating at –56 °C and 0.036 mbar 
vacuum pressure. The samples were removed after 18 h and stored in the fridge at 4 °C  
until analysis.  
 
2.2.4. Spray Drying 
 
 Trehalose dihydrate was added to the trastuzumab solutions at a weight ratio of 1:1 and resultant 
solutions were spray-dried using a Mini Spray Dryer B-290 (Buchi, Switzerland) at an inlet 
temperature of 170 °C, aspirator rate of 80%, and a feed-flow rate of 4 mL/min. Air was used as the 
drying medium and the outlet temperature recorded was 76 °C.  
 
2.3. Preparation of Nano- and Microparticles Containing Trastuzumab 
 
Trastuzumab containing PLGA nanoparticles were prepared by a double emulsion solvent 
evaporation method adapted from Ramtoola et al., [24]. Trastuzumab (15 mg) was dissolved in 1% 
w/v aqueous PVA and was added to 135mg of PLGA in ethyl acetate and sonicated at 1 Watt for 1 min 
to form a water-in-oil (w/o) emulsion which was then emulsified in 2.5% w/v aqueous PVA solution to 
form a double water-in-oil-in-water (w/o/w) emulsion using sonication at 1 watt for 1 min. The w/o/w 
emulsion was added to 1% w/v aqueous PVA and homogenised using an Ultra Turrax high speed 
homogeniser (TP 25, Janke-Kunkel, Staufen, Germany) operating at a speed of 13,500 rpm for 3 min. 
The emulsion formed was added to the deionised water and stirred for 8 h to allow solvent evaporation. 
The nanoparticles were recovered by centrifugation (Rotina 35 R, Hettich Zentrifugen, Tuttilingen, 
Germany) washed with deionised water to remove residual PVA and lyophilised as per lyophilisation 
protocol in section 2.2. Nanoparticles were stored at 4 °C until required. 
Trastuzumab-containing chitosan microparticles at a theoretical trastuzumab loading of 5.6% w/w 
of chitosan were prepared as described previously [24]. Briefly, Trastuzumab solution containing d-
(+)-trehalose dihydrate at a weight ratio of 1:1 was added to a solution of chitosan in 1% v/v aqueous 
acetic acid. The trastuzumab/chitosan solution was spray dried at a feed flow rate of 4 mL/min and an 
inlet temperature of 170 °C. The outlet temperature was monitored during the spray drying process and 
was found to be 83 °C. Nanoparticles formulated were characterised for their size using a zetasizer 
(Nanoseries, Nano-ZS; Malvern Instruments) while microparticles were sized using a mastersizer 
(Malvern Instruments, Malvern, Worcestershire, UK). The surface morphology of the particles was 
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examined by scanning electron microscopy (Hitachi Scanning Electron Microscope (model S 3500N), 
Tokyo, Japan). 
Trastuzumab from the nanoparticles was extracted by adding 0.5 mL ethyl acetate, followed by the 
addition of DI water. Samples were vortexed at 1400 rpm for 10 min, centrifuged at 11000 rpm for  
5 min to form a two phase solution. The aqueous layer was removed by syringe for assay of drug 
content using the bicinchoninic assay kit (Pierce Thermo Scientific, Ireland) and analysis of structural 
integrity and bioactivity of trastuzumab. 
 
2.4. Analysis of Trastuzumab for Structural and Conformational Integrity  
 
Trastuzumab solutions before and after being subjected to the various mechanical stresses and 
trastuzumab extracts from micro and nanoparticles were analysed for structural or conformational 
changes using the methods described below.  
 
2.4.1. Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
SDS-PAGE was carried out using precast NuPAGE® Novex 4–12% Bis-Tris 1.0 mm Gel on XCell 
SureLock under reducing and non-reducing conditions as per the protocol from Invitrogen, CA, USA 
[25]. Approximately 1 µg (10 µL) of trastuzumab was loaded per well. The gel was stained with 
Coomassie Brilliant Blue R-250 staining solution (Bio-Rad, CA, USA) at 37 °C for 1 h in a shaker at 
100 rpm and later destained with destaining solution (Bio-Rad, CA, USA) for up to 3 h at 37 °C. 
 
2.4.2. Size Exclusion Chromatography (SEC) 
 
SEC-HPLC analysis as described previously by Tang et al. [26] was used to measure the structural 
integrity of trastuzumab samples and the trastuzumab concentration present in the samples. SEC-
HPLC was conducted using a BioSep SEC S 3000 (Phenomenex, UK) column with a Perkin Elmer 
Series 200 analytical system (USA) with UV detection at 280 nm. The mobile phase consisted of  
100 mM potassium phosphate, KH2PO4 (Sigma-Aldrich, Mo, USA), adjusted to pH 7.0 with 1 M 
NaOH (Merck, NJ, USA) and was run at a flow rate of 0.8 mL/min. The column was maintained in an 
oven at a temperature of 30 °C. Control trastuzumab solutions at a range of concentrations of 0.2 to  
4 mg/mL were analysed to give a calibration curve which was used to determine concentrations of 
trastuzumab in the samples studied. Reproducibility of injections (n = 6) was carried out at 0.4, 1 and  
4 mg/mL trastuzumab concentration. Control solutions and stressed samples were analysed in triplicate. 
 
2.4.3. Circular Dichroism (CD) 
 
Circular dichroism (CD) measurements were performed using an Aviv CD Spectrophotometer 410 
(Aviv Biomedical, Inc. New Jersey, USA). The stability of the secondary structure of trastuzumab for 
control trastuzumab solutions and trastuzumab samples at a concentration of 0.2 mg/mL in saline was 
probed using a quartz cell of 0.1 cm path length. The CD spectra for trastuzumab were collected in the 
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far-UV region (195 to 260 nm). After an accumulation of 5 scans at a scan rate of 1 nm per second, the 
scans were corrected by subtracting the blank.  
 
2.5. In Vitro Bioactivity Assay for Trastuzumab 
  
Trastuzumab bioactivity was determined by measuring the inhibition in cell proliferation of SK-
BR3 cells (passage 90), a human breast cancer cell line which over-expresses HER-2 as per the method 
described by Ozbay et al. 2010 [27]. SK-BR3 cells were grown in RPMI-1640 medium with 10% HI-
FBS (BioSera UK) and passaged once per week. The cells were seeded in 96-well plate (Sarstedt, USA) 
at a density of 1 × 104 cells/well. After the cells formed a monolayer at approximately 38 h, the 
medium was replaced by trastuzumab standards and samples of various concentrations diluted to give 
a dose response curve. The cells were incubated for 72 h after which 100 µL of 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent was added to 
each well and the plate incubated for 3 h. Absorbance was then read at 490 nm and converted to % 
inhibition of cell proliferation. The results are presented as log dose of trastuzumab (ug/mL) vs. % 
inhibition of cell proliferation (expressed as % of maximum trastuzumab (2mg/mL) mediated 
inhibition). Untreated cells (100 µL complete growth medium containing 10% FBS and  
100 µL saline) were set at 100% proliferation. 
3. Results and Discussion  
3.1. Effect of Mechanical/Shear Stress on Structural Integrity of Trastuzumab 
 
3.1.1. Effect of Sonication 
 
Sonication is a commonly used technique for enhancing dissolution rate, to deaggregate particles as 
well as to disrupt cell membranes or fragment DNA. It is also used in the formation of single or double 
emulsions during the formulation of biodegradable nanoparticles by the solvent evaporation process to 
encapsulate numerous therapeutic agents including proteins [28]. Sonication produces high frequency 
sound waves and has been reported to cause aggregation of proteins with molecular weight ranging 
from 13.7–66.4 kDa [11].  
In our study, sonication was not found to have any detrimental effect on trastuzumab structural 
integrity as was determined by SEC-HLPC and SDS-PAGE (Figures 1 and 2). No aggregation or 
degradation was observed when trastuzumab solution of 0.4 or 4 mg/mL was sonicated at low or high 
intensity of 1 and 3 watts. Increasing the exposure time of sonication at 1 Watt from 1 to 3 min for the 
trastuzumab 4 mg/mL solution showed no degradation or formation of soluble aggregate as a single 
band, corresponding to the molecular weight of ~150 kDa for native trastuzumab when analysed by 
SDS-PAGE. When reduced chemically using dithiothreitol, trastuzumab was fragmented into its 
subunits of ~25 kDa and ~50 kDa representing the light and heavy chains of trastuzumab monomer 
respectively (Figure 2, lane 5). 
 
Pharmaceutics 2011, 3                   
 
 
516
No change in retention time, additional peaks or significant decrease in trastuzumab monomer 
concentration was observed by SEC analysis (Table 1 and Figure 1 a,b). No soluble/reversible 
aggregates were detected by SEC or SDS-PAGE. Exposure of trastuzumab at low and high 
concentration of 0.4 and 4 mg/mL had no impact on the structural integrity of trastuzumab irrespective 
of sonication intensity or duration of exposure.  
 
Table 1. Concentration of trastuzumab monomer as determined by size exclusion 
chromatography (SEC) after subjected to various mechanical stress. Data shown as mean 
of n = 3 ± SD.  
Sample/stressed sample Level of stress Assayed trastuzumab 
monomer (mg/mL) 
(%) original 
trastuzumab 
monomer 
Trastuzumab (0.4 mg/mL) None 0.38 ± 0.01 100.0 
Trastuzumab (2 mg/mL) None 1.94 ± 0.03 100.0 
Trastuzumab (4 mg/mL) None 3.95 ± 0.04 100.0 
Sonicated (0.4 mg/mL) 1 Watt, 1 min 0.38 ± 0.02 100.6 ± 6.6 
Sonicated (4 mg/mL) 1 Watt, 1 min 3.94 ± 0.05 99.8 ± 1.2 
Freeze-thaw (0.4 mg/mL) 1 cycle 0.36 ± 0.01 94.8 ± 3.2 
Freeze-thaw (0.4 mg/mL) 3 cycles 0.35 ± 0.00 94.3 ± 1.0 
Freeze-thaw (0.4 mg/mL) 6 cycles 0.34 ± 0.02 91.3 ± 5.1 
Freeze-thaw (4 mg/mL) 1 cycle 3.94 ± 0.02 99.8 ± 0.4 
Trastuzumab (2 mg/mL) lyophilized 1.89 ± 0.01 97.3 ± 0.5 
 
Figure 1. Size exclusion chromatography (SEC) chromatogram of native (control; light 
blue) trastuzumab overlayed with (a) 0.4 mg/mL trastuzumab sonicated at 1 Watt 1 min (b) 
4.0 mg/mL trastuzumab sonicated at 1 Watt 1 min (c) trastuzumab freeze-thawed and (d) 
tratsuzumab freeze-dried. 
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Figure 2. SDS-PAGE showing: molecular weight ladder (Lane 1), native trastuzumab 
(Lanes 2–4), chemically reduced trastuzumab (Lane 5), spray-dried trastuzumab (Lane 6), 
trastuzumab freeze-thawed x 6 cycles (Lanes 7–8), trastuzumab sonicated at; 1 Watt × 1 
min (Lane 9), 3 Watt × 1 min (Lane 10), at 1 Watts × 3 min (Lanes 11-12) and trastuzumab 
extracted from Poly-lactide-co-glycolide (PLGA) nanoparticles (Lane 13).  
 
 
 
 
 
 
 
                                   
 
 
 
 
Circular dichroism was used to assess changes to the secondary structural conformation of 
trastuzumab following sonication. The circular dichroism (CD) spectra of the native trastuzumab 
showed an intensity that equals zero at 206 nm, a minimum at 217 nm and a broad shoulder around 
230 nm indicating that the β-sheet is the most dominant secondary structure present (Table 2 and 
Figure 3). These results were consistent with that reported by Veermeer et al., [5], for the native IgG 
molecule. Trastuzumab sonicated at the highest intensity of 3 Watts for 3 min showed no change in the 
wavelength at zero intensity, minima or broad shoulder when compared with the spectrum observed 
for native trastuzumab. Therefore, sonication of trastuzumab does not lead to the change in the 
secondary structural conformation of trastuzumab confirming that trastuzumab remains structurally 
and conformationally intact when exposed to sonication stress at the intensity and duration mentioned.  
Table 2. Circular dichroism (CD) analysis of trastuzumab subjected to various mechanical stresses. 
Trastuzumab samples Wavelength at zero 
intensity 
Spectra minima Broad shoulder 
Native trastuzumab 207 nm 216 nm 235 nm 
Sonicated at 3 Watts for 3 min 206 nm 216 nm 236 nm 
Freeze-thaw by 6 cycles 206 nm 215 nm 234 nm 
Freeze-dried 206 nm 215 nm 236 nm 
Spray-dried 206 nm 215 nm 234 nm 
Extract from PLGA nanoparticles 206 nm 217 nm 235 nm 
Extract from chitosan microparticles 206 nm 217 nm 235 nm 
Denatured Trastuzumab  204 nm 215 nm 230 nm 
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Figure 3. Circular dichroism (CD) spectra analysis of trastuzumab subjected to various 
mechanical stresses. 
 
 
3.1.2. Effect of Freeze-Thaw Cycle 
  
During freezing, pH changes due to crystallisation of buffer components can occur and can result in 
the denaturation, aggregation and precipitation of proteins. In addition during freezing, new ice 
solution interfaces are created which increase the potential for aggregation and denaturation. Pikal-
Cleland et al., [29] reports irreversible damage to the structure, conformation and biological activity of 
both monomeric and tetrameric β-galactosidase in sodium phosphate buffer as a result of a decrease in 
pH during the freezing stage of freeze thawing experiments. Barnard et al., [30] showed that when 
IgG2 solution in PBS at a pH 7.0 was frozen and thawed from –20 °C to room temperature for three 
cycles, insoluble aggregates were formed. 
In our study exposure of trastuzumab to freeze-thawing had no detrimental effect on trastuzumab 
structural integrity and no soluble or insoluble aggregates were observed by SEC and SDS-PAGE 
(Figures 1c and 2). The SEC analysis of 0.4 mg/mL trastuzumab exposed to one, three or six freeze-
thaw cycles showed a small decrease (<9%) in the monomer peak although no change in retention time 
or presence of additional peaks was observed when compared to the native trastuzumab (Table 1 and 
Figure 1c). It is possible that some soluble or reversible aggregates were formed at this low 
concentration but were below the detection limit of SEC and SDS-PAGE. The structural integrity of 
trastuzumab at the higher concentration of 4 mg/mL was maintained after exposure to freeze thaw with 
little or no loss in monomer concentration. Trastuzumab at 0.4 and 4 mg/mL subjected to six freeze-
thaw cycles showed one band corresponding to the native trastuzumab and no additional bands on 
SDS-PAGE gel was observed (Figure 2). The conformational integrity of trastuzumab after exposure 
to six freeze thaw cycles was confirmed by CD analysis as no change in its spectrum was observed 
when compared to that of native trastuzumab (Table 2 and Figure 3).  
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3.1.3. Effect of Lyophilisation (Freeze-Drying)  
 
Lyophilisation, or freeze-drying, is a commonly used method for the preservation of labile materials 
such as proteins in a dehydrated form. Freeze-drying is also a common recovery method for protein 
encapsulated in nanoparticles. Lyophilisation is generally carried out in the presence of a 
cryoprotectant such as sucrose, trehalose or sorbitol to immobilize the protein in a glassy matrix and 
maintain the bioactivity of the protein molecules. 
Lyophilisation of trastuzumab solutions showed no decrease in the monomer concentration, when 
compared to native trastuzumab (Table 1 and Figure 1d). Similarly, when analysed by CD no 
significant differences in the CD spectrum was observed when compared to the native trastuzumab 
(Table 2 and Figure 3) confirming no conformational changes of the trastuzumab molecule occurred 
when lyophilised. Trastuzumab is marketed as the freeze-dried form ready for re-constitution. When 
lyophilised after reconstitution and diluted in saline, no detrimental effect on trastuzumab structural 
integrity was observed. The presence of additional sodium chloride in the reconstituted and diluted 
trastuzumab solutions did not adversely affect the trastuzumab during freezing/drying process.  
 
3.1.4. Effect of Spray Drying 
  
Spray drying is commonly utilized in the drying of actives and excipients in the pharmaceutical 
industry. It is also extensively used for granulation and microencapsulation. Spray drying of biological 
molecules is often associated with potential instability of these molecules as a result of their exposure 
to the high temperatures used. In addition the proteins are subject to considerable shear forces due to 
the spraying mechanism as the solutions are fluidised through a fine nozzle to form the droplets in 
contact with drying air or nitrogen. Chen et al. [31] reported that antibodies are vulnerable to 
denaturation via thermal stress. Adler et al. [32] showed that the stability of the model protein lactate 
dehydrogenase (LDH) during spray-drying was a function of the spray-drying temperature and drying 
time and was related to the presence of the protein at the liquid/air interface. Adler et al. [32] reported 
that the addition of suitable surfactant such as polysorbate 80 can prevent the LDH protein from 
appearing at the surface of the droplets and hence prevent protein inactivation. 
Spray drying of trastuzumab solution was performed at an inlet temperature of 170 °C and a flow 
rate of 4 mL/min using heated air as drying medium. Interestingly, no detrimental effect on 
trastuzumab structural integrity was observed when analysed by SDS-PAGE and CD (Lane 6, Figure 1 
and Figure 3). No difference between the spray dried sample was found compared to the native 
trastuzumab, reflecting no aggregation, degradation or change in the trastuzumab conformation. 
Vermeer et al. [5] reported that, at temperatures above 65 °C, the wavelength at zero intensity shifts to 
a lower value of less than 200 nm, compared to 206 nm for the native trastuzumab and this is 
indicative of a less ordered structure. In our study, the wavelength at zero intensity was at 206 nm for 
the spray dried trastuzumab and was 207 nm for the native trastuzumab. When trastuzumab solution 
was incubated at a temperature of 75 °C a shift of the wavelength at zero intensity from 207 nm to  
204 nm was observed (Figure 3 and Table 2) indicating a shift to a less ordered structure of the 
trastuzumab at the incubation temperature. The stability of trastuzumab at the high spray drying 
temperature of 170 °C is probably due to the short exposure time, of seconds, of the mAb to this 
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elevated temperature. In addition trehalose which is used as a cryoprotectant during lyophilisation of 
proteins, was added to the tratsuzumab solution and this may have acted as a protectant during  
spray drying. 
The structural stability of each monoclonal antibody varies with respect to its resistance to stress, 
for example it has been reported that trastuzumab when subjected to temperatures of 70 degrees for 15 
min did not lead to aggregation or decomposition [33]. It is possible therefore that trastuzumab has a 
higher resistance to both shear and temperature stressors.   
 
3.2. Effect of Microencapsulation Shear and Temperature on the Structural Integrity of Trastuzumab 
Trastuzumab containing nano and microparticles formulated showed similar particle size and 
morphology as previously reported for similar particulate formulations from our research group [24]. 
The nanoparticles had a diameter of 206.48 ± 0.60 nm and were smooth and spherical (Figure 4 a). The 
spray dried microparticles formed had a median diameter of 13.22 ± 0.73 µm and were spherical with a 
puckered surface (Figure 4 b). 
Figure 4. Scanning electron micrographs of trastuzumab containing (a) PLGA 
nanoparticles, (b) chitosan microparticles. 
 
 
 
The trastuzumab content of the nanoparticles was found to be 13.7 ± 1.7% w/w. The trastuzumab 
loading of the microparticles was in the range of 6.1–6.8% w/w. 
The application of single stressors as described above was not found to affect the structural integrity 
of trastuzumab and did not result in aggregate formation. During micro/ nanoparticle formulation, 
depending on the method used, the active can be subject to multiple successive stressors which can 
include sonication, homogenization, centrifugation, lyophilisation, contact with organic solvents as in 
the case of solvent evaporation from emulsion systems. When using spray drying as 
microencapsulation technique, the active is subject to shearing through a nozzle in addition to exposure 
to high temperature above 100 °C for aqueous solutions. Van de Weert et al. [34] reported that the use 
of an oil-in-oil emulsion may reduce potential denaturation stress when compared to the use of 
aqueous solutions as the outer phase.  
In our study, a double emulsion, a water-oil-water (w/o/w) emulsion, was used to formulate 
particles containing trastuzumab using the biodegradable polymer PLGA dissolved in ethylacetate. 
The w/o/w emulsion was formed by sonication at 1 watt over a total time of 2 min followed by high 
shear homogenization at 13,500 rpm for 3 min. The emulsion was subsequently subject to 
centrifugation followed by lyophilisation.  
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SDS-PAGE analysis on the trastuzumab extracted from the nanoparticles showed a single band 
(Lanes 13, Figure 2) similar to that of native trastuzumab. No aggregate or fragmentation of the 
extracted trastuzumab was observed suggesting that structural integrity was maintained during the 
encapsulation of trastuzumab, irrespective of its exposure to multiple stressors. When examined by CD, 
the spectrum for the trastuzumab extracted from particles was found to be similar to that of the native 
trastuzumab (Figure 3) with no significant shift at any of the identified wavelength of zero intensity, 
minimum and shoulder (Table 2) showing the retention of the β-sheet dominance of the secondary 
structure and conformation.   
Similarly, microencapsulation of trastuzumab with chitosan polymer by spray drying at 170 °C was 
not found to affect the structural integrity or secondary structure of trastuzumab.  The findings in this 
study are surprising as proteins and in particular mAbs are generally considered labile molecules too 
fragile for exposure to the stressors examined in this study. 
 
3.3. Evaluation of the Effect of Processing Stressors on the Biological Activity of Trastuzumab 
 
While the results above have shown absence of aggregate formation, denaturation and degradation 
or fragmentation of trastuzumab, the effect on biological activity of the molecule is critical as it 
dictates its in vivo performance. Therefore the effectiveness of trastuzumab to inhibit cell proliferation 
of SK-BR3 cells, following its exposure to the various stressors was studied and was compared with 
that of native or control trastuzumab.  
No significant difference in the biological activity of trastuzumab was observed when subjected to 
sonication, spray drying or after formulation as nano or microparticles (p > 0.05), One Way ANOVA, 
Figures 5 a,b). The exposure of trastuzumab to any of these stressors studied singly or in combination 
or its exposure to spray drying at elevated temperature of 170 °C therefore did not affect its biological 
activity. This supports our earlier observations that no loss of structure or conformation of trastuzumab 
occurred when exposed to one or more of the physical/thermal stress studied. 
Figure 5. (a) The effect of sonication and nanoparticle formulation on the trastuzumab 
mediated inhibition of SK-BR3 cells. (b) The effect of spray drying and microparticle 
formulation on the trastuzumab mediated inhibition of SK-BR3 cells. Data shown as mean 
of n = 3 ± SD.  
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4. Conclusions  
Instability is an inherent characteristic of protein molecules which impacts on the processing 
conditions and techniques used in their manufacture. This instability is often a barrier to their further 
development as micro- and nanoparticles for controlled and targeted delivery. In this study, we 
examined the effect of single or multiple shear/thermal stresses commonly encountered in 
pharmaceutical and microencapsulation processes on a model mAb, trastuzumab. Our results showed 
that trastuzumab was less vulnerable to shear/thermal processing conditions than was expected. 
Trastuzumab was not adversely affected by exposure to any of the stressors either singly or in 
combination. The presence of trehalose probably acted as a stabiliser for tratsuzumab during spray 
drying. According to our results, it appears that trastuzumab may be a protein which is resistant to 
physical stresses and to short exposure to thermal stresses. It is possible that other mAbs may be 
similarly less vulnerable to certain stresses. Interestingly, the findings in this study also suggest that it 
may be possible to utilise other drying technologies such as spray drying besides lyophilisation in their 
manufacture. The potential of spray drying for the formulation and manufacture of therapeutic peptides 
and proteins therefore warrants further consideration. 
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